Vanishing Brain Lesions In A Patient With Vision Loss And Ataxia A Case Of Cns Lymphoma With Corticosteroid Related Regression
Elavarasi, A., Rao, S., Ramakrishnan, S., & Bhatt, D. (2022). Vanishing Brain Lesions in a Patient with Vision Loss and Ataxia: A Case of CNS Lymphoma with Corticosteroid Related Regression. Annals of Indian Academy of Neurology, 25(3), 536–540. https://doi.org/10.4103/aian.aian_949_21
View Original Source →Abstract
Relapsing demyelinating syndromes (RDS) in children encompass a diverse spectrum of entities including multiple sclerosis (MS) acute disseminated encephalomyelitis (ADEM), aquaporin-4 antibody associated neuromyelitis optica spectrum disorder (AQP4-NMOSD) and myelin oligodendrocyte glycoprotein antibody disease (MOG-AD). In addition to these, there are "antibody-negative" demyelinating syndromes which are yet to be fully characterized and defined. The paucity of specific biomarkers and overlap in clinical presentations makes the distinction between these disease entities difficult at initial presentation and, as such, there is a heavy reliance on magnetic resonance imaging (MRI) findings to satisfy the criteria for treatment initiation and optimization. Misdiagnosis is not uncommon and is usually related to the inaccurate application of criteria or failure to identify potential clinical and radiological mimics. It is also notable that there are instances where AQP4 and MOG antibody testing may be falsely negative during initial clinical episodes, further complicating the issue. This article illustrates the typical clinico-radiological phenotypes associated with the known pediatric RDS at presentation and describes the neuroimaging mimics of these using a pattern-based approach in the brain, optic nerves, and spinal cord. Practical guidance on key distinguishing features in the form of clinical and radiological red flags are incorporated. A subsection on clinical mimics with characteristic imaging patterns that assist in establishing alternative diagnoses is also included.
Case Details
Disease Location
Brain
Personal Characteristics
46‐year‐old man
Clinical Characteristics
Presented with headache and 15 days later ataxia and diplopia developing over a week. Provisional diagnosis of primary cns demyelinating illness was made based on imaging and was started on intravenous methylprednisolone followed by a short course of oral prednisolone with which his symptoms resolved. Three months later, he developed complete vision loss in the right eye over 1 week. He had features of retinal necrosis. A diagnosis of cytomegalovirus (cmv) retinitis was made and was treated with valacyclovir and intravitreal triamcinolone. Vision improved partially to 6/36 over the next 3 months, when he developed complete vision loss in the left eye. This was also treated with valacyclovir and corticosteroids and there was a partial improvement in vision to 5/60. Seven months later, he again developed ataxia, dysarthria, and headache. Brain imaging was repeated which showed a contrast-enhancing well‐demarcated lesion in the cerebellar vermis which was hyperintense on flair and was diffusion restricting, while the cerebellar hemispheric lesions seen in the previous imaging, seen during the first visit, had resolved. He received injectable methylprednisolone. A biopsy of the left cerebellar lesion was performed which revealed a high-grade non‐hodgkin’s b cell lymphoma. The patient was treated with modified de angelis’ protocol for primary cns lymphoma with rituximab, methotrexate, procarbazine, vincristine and prednisolone. After 6 cycles of chemotherapy and two fractions of whole brain radiotherapy, he was completely asymptomatic except for gaze‐evoked nystagmus at 18 months follow up.
Remission Characteristics
Seven months later the cerebellar hemispheric lesions seen in the previous imaging, seen during the first visit, had resolved.
Treatment & Mechanisms
Proposed Remission Mechanisms
Some cns lymphomas may respond dramatically to steroids and even a single dose can lead the tumour to melt away.
Clinical Treatment
Methylprednisolone, prednisolone. Valacyclovir, trimacinolone. Biopsy rituximab, methotrexate, procarbazine, vincristine and prednisolone radiotherapy.